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Metabolic syndrome is a critical risk factor for the development of type 2 diabetes 
mellitus and cardiovascular disease, two of the leading causes of death in the United 
States. With over one third of the adult population currently affected, this syndrome 
poses a serious health and economic burden. Lifestyle modification is the primary 
treatment, however only 50% maintain adherence. A single pharmacological therapy such 
as canagliflozin may overcome this lack of treatment adherence. Our purpose is to 
establish a difference between canagliflozin 300 milligrams daily plus lifestyle 
modification education and lifestyle modification education alone for the remission 
of metabolic syndrome in nondiabetic adults after one year. We will conduct a 
double-blind, randomized placebo-controlled trial in order to assess for this primary 
endpoint. This study has the capability to improve the current treatment of metabolic 
syndrome and potentially prevent the development of type 2 diabetes mellitus and 



















Chapter 1 – Introduction 
1.1 Background:  
Metabolic syndrome (MetS) is a cluster of cardiovascular risk factors comprised 
of obesity, dyslipidemia, hypertension, and glucose intolerance.1,2 The United States (US) 
prevalence of MetS in adults (18 years) is reaching pandemic proportions, increasing 
from 25.3% in 1988-1994 to 34.2% in 2007-2012, and is still expected to rise.3,4 Further, 
data from the Third National Health and Nutrition Examination Survey (NHANES III) 
indicates that prevalence increases with age, with 44% of the US population over 50 
years old meeting MetS criteria.5  
Identifying MetS in the population is clinically beneficial for several reasons. The 
discovery allows for the recognition of those with an increased risk of cardiovascular 
disease (CVD) and type 2 diabetes mellitus (T2DM), with a higher risk being associated 
with a greater number of risk factors.6 Plus, the reversible nature of MetS allows for a 
unique opportunity to intervene and reduce the health and economic burdens of CVD and 
T2DM on the US population.4 
 The cost of MetS to both the patient and the healthcare system is substantial. One 
study found that those with MetS spend on average about $2,000 more annually than 
those without ($5,732 vs. $3,581).7 When examining the financial burden of the 
syndrome on those 65 years and older, one study found that total cost to Medicare for 
those with MetS was 20% higher than those without ($40,873 vs. $33,010).8 Once there 
is progression to CVD or T2DM, these costs can be expected to rise. As chronic diseases, 
they take a huge economic toll, costing hundreds of billions of dollars to the healthcare 
system and billions lost in productivity.9 
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In order to appropriately address MetS, it is important to understand its etiology. 
Though the exact underlying cause is unknown, the syndrome is widely considered to be 
a result of insulin resistance. Factors contributing to insulin resistance include both 
genetic predispositions and environmental components. Over time, insulin resistance 
leads to hyperglycemia and salt overload, which can then result in hypertension, 
lipogenesis, and a worsened lipid profile. Treatment targeted towards these initial causes 
of the syndrome will likely relieve some of the harm and improve outcomes.10  
Ultimately, the goals of management for MetS are to reduce the risk of 
progression to CVD and T2DM, two of the leading causes of death and disability in the 
US.9 The current primary treatment is lifestyle modification, which includes weight loss, 
moderately intense physical activity, and a highly structured antiatherogenic diet.11 
Generally, a 10% reduction in weight is encouraged through lifestyle modification; 
however, the higher the risk of progression to additional diseases, the more likely weight 
loss drugs will be considered for use.12  
If tightly followed and maintained, lifestyle modification offers the greatest 
potential for controlling the pandemic of MetS and has been shown to improve all 
metabolic abnormalities of the syndrome.4,13,14 But in spite of this promising evidence, 
nonadherence to lifestyle changes is near 50%, and many patients end up requiring risk-
reducing drugs that target each individual risk factor.15,16 But this presents a 
consequential problem of polypharmacy, which comes with its own risks of increased 
costs, decreased compliance, and adverse drug reactions.14,17 
The inverse relationship of number of medications to medication adherence has 
been cited numerous times in the literature. Drugs frequently noted in these studies were 
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those that would target the risk factors of MetS: antihypertensives, antidiabetics, and 
lipid-lowering agents.18-25 Consequently, the ideal pharmacologic solution to improve 
MetS outcomes would be a single drug that simultaneously reduces weight, glucose 
levels, blood pressure, triglycerides, and raises high-density lipoprotein (HDL) 
cholesterol.14,26 
Sodium-glucose cotransporter 2 inhibitors (SGLT2is), are novel oral antidiabetic 
drugs that work by inhibiting the sodium-glucose cotransporter 2 in the proximal 
collecting tubule of the kidney. The inhibition of this transporter prevents the 
reabsorption of both sodium and glucose, facilitating their excretion into the urine. 
Through this mechanism, SGLT2is have the potential to target all five components of 
MetS, thereby reducing the rate of progression to poor outcomes such as CVD and 
T2DM.27  
1.2 Statement of the Problem 
Thus far, there has been no randomized controlled trial (RCT) in the US to assess the 
efficacy of SGLT2is as the single pharmacologic therapy for the treatment of MetS. Any 
evidence for this potential indication is found in preclinical trials, retrospective analyses or 
inferred from studies with different primary objectives. While evidence from these studies 
and analyses is promising,28 an RCT is required to evaluate SGLT2is in comparison to what 
is currently being practiced as the primary treatment: lifestyle modification education. Such 
an RCT is particularly pressing given the noncompliance and nonadherence rates to the 
primary treatment, as well as the increased risk of progression to T2DM and CVD with a 
MetS diagnosis. In comparison to other Food and Drug Administration (FDA)-approved 
 4 
SGLT2is, canagliflozin has shown slightly more beneficial effects on metabolic 
abnormalities and is therefore the most promising SGLT2i for the proposed study.29-31 
1.3 Goals and Objectives 
The purpose of the proposed study is to establish a difference between 
canagliflozin 300 mg daily plus lifestyle modification education and lifestyle 
modification education alone for the remission of MetS in nondiabetic adults. This 
potential difference will be measured using the following primary outcome: remission of 
MetS in nondiabetic adults after one year (represented as incidence proportions). The 
results of this primary outcome will serve as a foundation for the use of canagliflozin in 
the treatment of nondiabetic adults with MetS and inform the drug’s role in the 
prevention of T2DM and CVD development.  
Secondary outcomes will include fasting plasma glucose (FPG), waist 
circumference, blood pressure, triglyceride level, HDL cholesterol, C-reactive protein 
(CRP) level, insulin resistance, glycated hemoglobin (hA1C), and change in diet and 
exercise. Adverse events to be monitored include genital mycotic infection and 
amputations, among others. Measuring these outcomes and events will achieve our goal 
of quantifying the effect of canagliflozin 300 mg on metabolic abnormalities in 
nondiabetic adults after one year, identify possibly modifying effects on the outcome, and 
clarify canagliflozin’s safety profile.  
1.4 Hypothesis 
There will be a difference in the proportion of nondiabetic adults who achieve 
remission of MetS after one year of initiation of canagliflozin 300 mg daily plus lifestyle 
modification education compared to lifestyle modification education alone.  
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1.5 Definitions 
- MetS: meeting 3 or more of the following criteria: 
o Impaired Fasting Glucose (IFG) (FPG 100-125 mg/dL)  
o Abdominal obesity (waist circumference > 40 inches in men and > 35 
inches in women) 
o Blood pressure  135/85 mmHg 
o Triglycerides  150 mg/dL 
o HDL cholesterol < 40 mg/dL in men and <50 mg/dL in women 
- Remission of MetS: meeting  ≤ 2 MetS criteria (listed above) 
- Lifestyle modification education: Unstructured advice delivered by our research 
team’s physicians emphasizing the importance of a healthy lifestyle. Topics to be 
discussed include smoking and alcohol cessation, as well as proper exercise, 
eating, and sleeping habits. All research team physicians will be educated on the 
Centers for Disease Control and Prevention’s (CDC) National Diabetes 
Prevention Program curriculum32 before delivering the lifestyle modification 
education.  
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Chapter 2 – Literature Review 
2.1 Introduction 
To date, there are no studies in the US evaluating the use of SGLT2is as the single 
pharmacologic therapy versus the current primary recommendations for the treatment of 
metabolic syndrome (MetS). The purpose of this literature review is to summarize and 
critically evaluate prior research pertaining to this topic. The review of literature was 
performed from August 2019 to June 2020 using PubMed, Ovid and Embase databases. 
Systematic reviews, meta-analyses, and RCTs were included. Only results written in the 
English language were reviewed. The following MeSH terms were utilized: 
Metabolic syndrome, Syndrome X, MetS, Type 2 Diabetes Mellitus, T2DM, 
Impaired Fasting Glucose, Gliflozins, SGLT2i, SGLT2 inhibitor, Sodium Glucose 
Cotransporter-2 Inhibitor, Empagliflozin, Canagliflozin, Dapagliflozin 
2.2 Brief overview of Metabolic Syndrome and Its Implications 
 MetS, as defined by the National Cholesterol Education Program (NCEP) Adult 
Treatment Panel III (ATP III), is a constellation of three or more risk factors for T2DM 
and CVD, which include obesity (waist circumference >40 inches for men and >35 
inches for women), high triglycerides (150 mg/dL), low HDL cholesterol (<40 mg/dL in 
men and <50 mg/dL in women), hypertension (blood pressure 130/85 mmHg), and 
glucose intolerance (fasting plasma glucose 100 mg/dL).1,2 The syndrome results from a 
lack of physical activity, poor diet, and genetic predisposition. These habits and inherent 
susceptibility, over time, lead to insulin resistance and a chronic inflammatory state, 
which ultimately presents as the vascular damage and autonomic dysfunction consistent 
with MetS.3  
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The strong association between MetS and the risk of development of T2DM has 
been well-documented. In a meta-analysis of prospective cohort studies, the relative risk 
(RR) of developing T2DM with a diagnosis of MetS ranged from 3.53 to 5.17 depending 
on the criteria used to define MetS. This risk also increases with the number of metabolic 
abnormalities one has. The same meta-analysis found that compared to those without any 
abnormality, the RR for developing T2DM for those with four or five abnormalities using 
the NCEP/ATPIII definition ranged from 10.88 to 24.4. This meta-analysis incorporated 
multiethnic prospective studies to draw these conclusions, which allows these results to 
be applied to a considerably heterogeneous population.4  
Evidence for the risk of CVD with a MetS diagnosis is well-supported in the 
literature. In a national cross-sectional study examining the association between MetS 
and CVD, Ninomiya et al. found that those with MetS were twice as likely to have a 
stroke or myocardial infarction (MI) (odds ratio [OR] 2.05; 95% confidence interval [CI], 
1.64 to 2.57) than those without the syndrome. These results, though significant, are 
limited by both poor internal validity due to potential recall biases and its inherent 
inability to draw a causal relationship between the predictor variables and outcomes.5 
Lakka et al. sought to better identify a causal relationship between MetS and death due to 
CVD and coronary heart disease (CHD) by conducting a prospective study following 
~1200 Finnish men over the average course of 11.4 years. They concluded that men with 
MetS were almost 3 times more likely to die of CHD and 2.5 times more likely to die of 
CVD. Though this study is difficult to generalize, major strengths include its longitudinal 
design and exclusion of men with T2DM and CVD at baseline.6 
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For those who achieve remission of MetS, the risk of T2DM and CVD are 
significantly reduced. This phenomenon was observed by Huh et al. (2019) with a large 
prospective cohort study investigating change in MetS status on 10-year risk of incident 
T2DM in a Korean population. The authors followed 7,317 subjects to determine their 
change in MetS status after a two-year period and group them into four categories: non-
MetS, incident MetS, resolved MetS, and persistent MetS. Using a Cox proportional-
hazards analysis, Huh et al. found that the persistent MetS group showed the highest 
incidence risk of T2DM (hazard ratio [HR] 1.98; 95% CI, 1.50 to 2.61), and the resolved 
MetS group showed a decreased incidence risk of T2DM (HR 1.28; 95% CI, 0.92 to 
1.79). The difference between these two groups was statistically significant (p <0.0001). 
Seeing as T2DM is a known risk factor for CVD,7 it may be inferred from these results 
that the resolved MetS group not only had a decreased incidence risk of T2DM, but also 
of CVD. These results may even be underestimated due to loss to follow-up. Because of 
the homogenous sample, these results should be applied to more diverse populations with 
caution. However, the findings of this study should not be downplayed, as they suggest 
that treating MetS may prevent T2DM in practice.8 
Park et. al. further demonstrated the favorable effects of achieving remission of 
MetS in a 2019 retrospective cohort study investigating the association between MetS 
status and major adverse cardiovascular events (MACE), including MI, stroke, and 
revascularization. From the health data of 9,553,042 Koreans, Park et. al. concluded that 
those who achieved remission of MetS had a significantly lower (p <0.001) MACE risk 
(adjusted incidence rate ratio [IRR] 1.48; 95% CI, 1.44 to 1.51) than those with persistent 
MetS (adjusted IRR 2.01; 95% CI 1.98 to 2.04).9 The major strength of this study is that 
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the findings came from a large nationwide database. At the same time, this serves as a 
limitation because the findings have only come from one nation. Nonetheless, the results 
of this study are noteworthy as they highlight the potential benefits of achieving 
remission of MetS.  
The importance of this syndrome is evident due to its striking prevalence and 
association with an increased risk of both T2DM and CVD and their complications. 
Therefore, effective treatment strategies are needed that target the components of the 
syndrome to prevent associated morbidity and mortality.8,10 Current management 
strategies practiced by clinicians include recommending lifestyle modification, as well as 
prescribing antihypertensives, lipid-lowering agents, and antidiabetics if felt necessary. 
These options will be reviewed in the following section.11 
2.3 Review of Current Strategies and Their Limitations 
2.3.1 Lifestyle Modification Therapy 
Although genetics play a role in the development of MetS, the syndrome often 
coincides with poor diet and physical inactivity. Therefore, initial treatments tend to 
focus on lifestyle modification therapy (diet, physical activity, behavioral strategies, etc.) 
before beginning drug therapy.11 If patients are motivated and willing to adhere to the 
recommendations, these changes offer substantial benefit.12-15 Pettman et al. 
demonstrated this in a 2008 RCT that compared a 16-week lifestyle program 
(intervention) to education on the national guidelines for healthy eating (control) for the 
treatment of MetS. The lifestyle program provided strategies in diet, exercise, and 
behavior, peer group support, free gym access, and one supervised exercise session each 
week. The results revealed that the intervention was effective in targeting the risk factors 
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of MetS, including obesity, blood pressure, total cholesterol, and plasma glucose. The 
study further demonstrated that greater attendance at information and exercise sessions 
was associated with greater reductions in body fat (p <0.001), diastolic blood pressure 
(p<0.001), systolic blood pressure (p = 0.01), total cholesterol (p <0.001), and plasma 
glucose (p < 0.001). While this study speaks to the benefits of lifestyle intervention, it 
was limited by its loss of 33 participants to follow-up (21.5%) and its assessment of 
compliance, which consisted of self-reported food and physical activity logs.16  
While the patients’ recognition of the benefits of lifestyle modifications is 
important, receiving brief information on healthy diet and exercise practices from a 
provider alone is not typically sufficient to inspire weight loss habits or lead to health 
benefits. A 2007 RCT conducted by Bo et al. demonstrated this by comparing a 
recommendation-based program of lifestyle intervention facilitated by trained 
professionals to advice given by family physicians to evaluate change in MetS prevalence 
after one year. The authors found that the intervention significantly reduced the 
prevalence of MetS compared to the controls (p <0.001). This emphasizes the inefficacy 
of advice given by primary care providers (PCPs), which was shown by the control 
group’s worsening metabolic variables and increasing cardiovascular risk over the year. 
These results were strengthened by the similarity of the two groups after randomization 
and by the sample size of 375 participants.17   
Not only is there a problem regarding noncompliance to lifestyle modification 
recommendations, but there is also the issue of nonadherence for those who do receive 
active interventions.18 For example, the Diabetes Prevention Program (DPP) Research 
Group determined that only about 20% of overweight individuals are successful at 
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maintaining weight loss after participating in intensive lifestyle intervention. Utilizing an 
RCT, the DPP Research Group followed approximately 1000 overweight individuals in 
an intensive lifestyle intervention for up to 4.6 years and found that the group, on 
average, maintained a weight loss of about 7 kg at 6 months, but only about 3 kg at 4 
years. This study upholds external validity by including a well-sized population that was 
racially and ethnically diverse, allowing the results to be generalized to the larger US 
population.19,20  
 Noncompliance and nonadherence to lifestyle modifications illustrate a need for 
other forms of therapy in the treatment of chronic illnesses such as MetS. Providers 
typically move towards pharmacotherapy when lifestyle modification proves to be 
inadequate, as it often does.21 Current drug therapies will be briefly reviewed in the 
following section.  
2.3.2 Pharmacotherapy  
 The American Heart Association and National Heart, Lung, and Blood Institute 
released practice guidelines regarding the choice of drug for each component of the 
syndrome for those with risk factors that are not controlled adequately by a patient’s 
lifestyle changes, as is the case for many.11,22 Such drugs typically include 
antihypertensives, lipid-lowering agents, and antidiabetics.11 As risk factors worsen, the 
number of drugs required to treat each risk factor tends to increase. For instance, once 
IFG has progressed to the diagnosis of T2DM in patients with MetS, often 10 
medications are required for treatment. At this point, a patient may not only be prescribed 
medications for the risk factors of MetS and its complications, but also for closely related 
conditions that follow (kidney disease, peripheral neuropathy, etc.).22 
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While the risk factors and complications of MetS must be treated, polypharmacy 
comes with its own dangers. In a systematic review, Rollason and Vogt identified six 
major clinical consequences of polypharmacy, for all of which the risk increases with 
number of medications taken: patient nonadherence, drug-drug interactions, increased 
risk of hospitalizations, medication errors, adverse drug events, and increased cost.23 
These unfavorable possibilities emphasize the need for a single drug that can target the 
five metabolic abnormalities of the syndrome and prevent further complications.  
Some argue that metformin is the single drug that can accomplish this task, 
however studies have shown that metformin is not equipped to significantly reduce the 
incidence of MetS when compared to placebo in an adult population.24 In a large RCT 
conducted by the DPP, 1711 volunteer participants were shown to have MetS at baseline 
and were equally randomized to three groups: intensive lifestyle intervention, metformin 
850 mg twice daily, and placebo. After a 3-year follow-up, resolution of MetS was only 
found to be significant in the intensive lifestyle intervention group (38%; p = 0.002) 
when compared to placebo. In the metformin group, only 23% of those with MetS at 
baseline had resolution (not significant, no p value provided). Importantly, it is possible 
that the only reason the intensive lifestyle found significant resolution when compared to 
placebo was due to the volunteer population, which arguably could have higher 
motivation to restore health than the general population.24    
2.4 The Promise of Sodium-Glucose Cotransporter 2 Inhibitors  
 The first SGLT2i, canagliflozin, was approved in 2013 by the FDA for the 
improvement of glycemic control and treatment of T2DM in adults. The following 
SGLT2is, dapagliflozin and empagliflozin, were approved for the same indication shortly 
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thereafter.25 As the class of the drug describes, SGLT2is work by inhibiting the sodium-
glucose cotransporter 2 in the proximal convoluted tubule of the nephron. Inhibition of 
this transporter primarily reduces the reabsorption of filtered glucose, but has also been 
noted to increase urinary sodium excretion.26 Through this mechanism, SGLT2is have 
been shown to positively influence not only fasting plasma glucose levels, but also body 
weight, blood pressure, and lipid levels.25 This section will review the current 
understanding of how SGLT2is are potential sole treatments for MetS.  
2.4.1 Impaired Fasting Glucose (Fasting Plasma Glucose 100 mg/dL) 
SGLT2is are currently indicated to treat T2DM and improve glycemic control.27 
Multiple studies have documented a larger decrease in FPG as an outcome of treatment 
with SGLT2is, regardless of which FDA approved drug, when compared to placebo.28-46 
To illustrate one study, Abdul-Ghani et al. identified eight subjects with IFG and 
assigned them empagliflozin 25 mg daily (treatment) for two weeks. FPG concentration 
was measured both 2 days and 14 days after the start of treatment. The results showed a 
statistically significant decrease in FPG in the IFG subjects at day 2 (from 110 ± 2 mg/dL 
to 103 ± 3 mg/dL; P < 0.01). This decrease was maintained at day 14.46 Although the 
short follow-up period and small sample size limit the impact of the aforementioned 
results, the CANTANA-M trial found a similar outcome but with a larger sample and 
longer length of study.47  
The CANTANA-M study was a randomized, double-blinded clinical trial 
evaluating the effects of canagliflozin 100 or 300 mg versus placebo over a 52-week 
period. From baseline to week 52, the authors found a dose-dependent reduction in least 
squares FPG mean changes (-27.4 mg/dL, 95% CI -31.8, -23.0 and -39.1 mg/dL, 95% CI 
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-43.6, -34.7 for 100 mg and 300 mg, respectively), and changes were seen as early as 6 
weeks into treatment. A total of 452 participants spanning 17 countries completed the 
entire 52-week study. This multi-country recruitment method serves this study well, as its 
results are more easily applied to a greater population.47  
2.4.2 Obesity (Waist Circumference: Men >40 inches, Women >35 inches) 
SGLT2is have also been shown to reduce weight from 1 kg to up to 5 kg, with a 
greater reduction in weight seen in those with a higher weight at baseline.37,48,49 While the 
weight loss might be attributable to volume depletion, it has also been shown to have 
come from visceral fat.48,50-52 The ASSIGN-K study demonstrated this reduction of 
visceral fat with 50 mg ipragliflozin (an SGLT2i currently approved in Japan) given to 
257 patients over 24 weeks, where in the first 4 weeks both body water and body fat 
decreased significantly, but from weeks 4-24, body fat continued to decrease while body 
water seemed to remain relatively unchanged. This study was both strengthened and 
limited by the sample population, which consisted only of Japanese patients with T2DM 
who had inadequate glycemic control with a hA1C >6% despite diet and exercise therapy 
or diet and exercise plus antidiabetic drug therapy for at least 12 weeks. This population 
strengthened the study by demonstrating an SGLT2i to be more effective than lifestyle 
modification. At the same time, this population only included one ethnicity, making it 
difficult to generalize to the US population.53  
In a different prospective intervention study conducted by Lee et. al., it was found 
that more than 70% of weight loss from ipragliflozin was attributable to reduction in 
body fat, while only about 20% was attributable to water loss. However, this was a 
single-arm study without placebo control, making the evaluation of the results more 
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difficult. Further, the body composition analyzer used in the study could not distinguish 
between visceral fat and subcutaneous fat.54 Nonetheless, these results are promising in 
that SGLT2is could effectively reduce waist circumference and address the obesity 
component of MetS.55,56 
2.4.3 Hypertension (Blood Pressure 130/85 mmHg) 
SGLT2is are not indicated as antihypertensive drugs. However, the blood 
pressure-lowering effect of SGLT2is has been documented in numerous studies and is 
thought to be due to the drug class’s mechanism of action, which facilitates both glucose- 
and sodium-induced osmotic diuresis.57 Regardless of the mechanism, these drugs have 
been noted to lower systolic blood pressure more than placebo.58 For instance, in a meta-
analysis of 38 clinical trials, Zaccardi et. al. found a reduction of up to -4.9 mmHg in 
systolic blood pressure and up to -2.0 in diastolic blood pressure in all SGLT2is versus 
placebo, with canagliflozin 300 mg producing the largest reduction.59  
The EMPA-REG OUTCOME trial was the first major double-blinded, placebo-
controlled RCT documenting the cardiovascular benefit of an SGLT2i. The study 
quantified blood pressure reduction as a consequence of empagliflozin at either 10 mg or 
25 mg. Regardless of the dose, empagliflozin reduced the mean systolic blood pressure 
by about 4 mmHg more than placebo after 52 weeks.60 The CANVAS Program study 
found similar results, as canagliflozin was noted to produce a mean difference systolic 
blood pressure of -3.93 mmHg more than placebo (p < 0.001, 95% CI, -4.30 to -3.56).61 
Though both the CANVAS Program and EMPA-REG OUTCOME trials included 
primarily white males, the large sample sizes (10,142 and 7,020, respectively) are able to 
provide more accurate mean values and smaller margins of error.  
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The blood pressure-lowering effect of SGLT2is has even been recognized by the 
FDA and is reported in the respective labeling documents.48 For example, the prescribing 
information for INVOKANA (canagliflozin) warns about the risk of hypotension for 
those who already have low blood pressure and supports this advisory with a double-
blind, placebo-controlled study. The study enrolled 584 patients and revealed statistically 
significant (p<0.001) mean changes from baseline in systolic blood pressure relative to 
placebo.58 This evidence further supports the use of SGLT2is as a mediator for a blood 
pressure-lowering effect.  
2.4.4 Lipid Disorders (Triglycerides 150 mg/dL; HDL Cholesterol: Men <40 mg/dL, 
Women <50 mg/dL) 
RCTs and meta-analyses have shown SGLT2is can address the last two 
components of MetS: low HDL cholesterol and high triglycerides. With regard to the 
former, the EMPA-REG OUTCOME and CANVAS trials both found small increases (~2 
mg/dL) in HDL cholesterol after 52 weeks of treatment with empagliflozin and 
canagliflozin, respectively.60,61 Another study found small improvements in HDL 
cholesterol (+2.1% to +9.3%) and small reductions in triglycerides (-0.9% to -10.6%) in 
patients receiving dapagliflozin.62 In the Zaccardi et. al. meta-analysis of 38 clinical 
trials, all SGLT2is slightly increased HDL cholesterol when compared with placebo, with 
the highest increase being 1.26 mg/dL. The same meta-analysis revealed that 
canagliflozin at all doses reduced triglyceride levels when compared with placebo.59 
These results support the beneficial effects of SGLT2is on lipid disorders.  
2.5 Limitations of Sodium-Glucose Cotransporter 2 Inhibitors 
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 No drug comes without report of adverse events, and SGLT2is are no exception. 
Though these drugs are generally well-tolerated, reported adverse events for this drug 
class range from non-serious, easily treatable infections to life-threatening complications. 
Genital mycotic infection with candida species is the most frequently reported adverse 
event and is observed in all FDA approved SGLT2is.63 The EMPA-REG OUTCOME 
trial reported a 3-4x increase in genital infection with candida species with pooled 
treatment of empagliflozin versus placebo. The increase in genital infection was 
statistically significant when compared with placebo (p <0.001) and was observed in both 
men and women.60 Similar statistically significant (p <0.001) outcomes were found in the 
CANVAS study, where the incidence of genital mycotic infections per 100 patient years 
for both men (3.5) and women (6.9) were 3-4x higher than men and women in the 
placebo group (1.1 and 1.8, respectively).61 The DECLARE study, which randomized 
17,160 participants with T2DM to dapagliflozin or placebo to evaluate the cardiovascular 
safety profile of dapagliflozin, also found a statistically significant (p <0.001) increase in 
genital infections in the treatment group. Seventy-six participants receiving 10 mg of 
dapagliflozin developed a genital infection, while only 9 participants receiving placebo 
developed a genital infection.64 While genital mycotic infections are the most frequently 
reported adverse event, they remain relatively uncommon, are easily treated, and rarely 
lead to discontinuation of the drug.63 
 Urinary tract infections (UTIs) also seem to be a cited adverse event in the 
literature. In 2015, the FDA even issued a Drug Safety Communication warning of the 
risk of complicated UTIs.65 However, when compared to placebo in RCTs, SGLT2is do 
not seem to significantly increase the risk of UTIs. This may be because SGLT2is are 
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typically prescribed to diabetic patients, and diabetic patients are at an increased risk of 
developing UTIs.63 Neither the EMPA-REG OUTCOME, CANVAS, nor the DECLARE 
study found statistically significant differences in reported UTIs in the treatment versus 
placebo groups.60,61,64 
 Other adverse events of concern include hypoglycemia, ketoacidosis, kidney 
injury, cancer (breast and bladder), urosepsis, bone fracture, and perineal necrotizing 
fasciitis (Fournier’s gangrene).63 Importantly, the EMPA-REG OUTCOME, CANVAS, 
and DECLARE studies (all large RCTs with a type 2 diabetic population) did not find 
any statistically significant differences in the incidences of these adverse events in the 
treatment versus placebo groups.60,61,64 Hypotension due to intravascular volume 
depletion was also noted to be balanced between the treatment and placebo groups.60,64 
Reports of these adverse events might be due to other drugs or a combination of SGLT2is 
plus other drugs that the type 2 diabetic population could be prescribed (i.e. insulin, 
diuretics, etc.). They might also be due to intercurrent stressors, such as illness or major 
surgery, or because of incorrect use of the drug, such as skipping days of treatment.63 
 Of note, canagliflozin has a black box warning (BBW) for lower limb 
amputations (LLA) in type 2 diabetics with established CVD as a consequence of results 
from the CANVAS study.58 Patients in this study were followed for an average of 5.7 
years, and those taking canagliflozin were found to be about twice as likely to have a 
LLA than those taking placebo (6.3 vs. 3.4 participants with amputation per 1000 patient-
years; HR 1.97; 95% CI, 1.41 to 2.75). These amputations most often occurred at the 
levels of the toe or metatarsal and in those with a history of amputation or peripheral 
vascular disease.61 No significant difference in amputations in empagliflozin or 
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dapagliflozin versus placebo were found in the EMPA-REG OUTCOME or DECLARE 
studies, respectively.60,64  
 Despite the BBW for LLA with the use of canagliflozin, SGLT2is have a 
relatively good safety profile. The most commonly reported adverse event, genital 
mycotic infections, is rather minor and can be easily treated. Serious adverse events are 
infrequent and can potentially be avoided with diligent prophylactic measures and patient 
education.    
2.6 Methodology Considerations for the Proposed Study 
2.6.1 Choice of Intervention Group  
Existing studies assessing for remission of MetS all do so following demanding 
interventions, including diet, exercise, combinations of both, bariatric surgery, and 
medications such as metformin.66 However, data regarding remission of MetS using the 
promising SGLT2is are scarce, with only one study of this nature being identified in the 
literature. Using the SGLT2i dapagliflozin, González-Ortiz et al. found a favorable 
remission rate of 58.3% in 12 participants after 12 weeks of intervention.67 The small 
sample size and short intervention period of this study prompt further investigation of 
SGLT2is for the remission of MetS.  
Following a thorough review of the literature, it has been determined that 
empagliflozin, canagliflozin, and dapagliflozin have consistent class effects and similar 
safety profiles. However, slight differences in their effects on metabolic abnormalities 
have been noted between them in various meta-analyses. For example, even though all 
SGLT2is are shown to reduce blood pressure, indirect data from a meta-analysis 
demonstrated that canagliflozin 300 mg daily led to greater reduction of systolic blood 
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pressure when compared with other SGLT2is, while no differences were reported for 
diastolic blood pressure among several SGLT2is.68 Two other meta-analyses both 
showed that canagliflozin had the largest favorable effects on lipid profiles (increased 
HDL and decreased triglycerides) when compared to empagliflozin and dapagliflozin.69,70  
For the purposes of this study, canagliflozin 300 mg tablet daily will be used due 
to its slightly more beneficial outcomes as evidenced in the aforementioned meta-
analyses. Because our study population consists of nondiabetics, the BBW for LLA with 
canagliflozin will likely not be of concern as it is noted specifically for patients diagnosed 
with T2DM and have or are at risk for CVD.58 Although 100 mg is the starting dose of 
canagliflozin, 300 mg has been shown to offer a greater benefit and will therefore be the 
dose offered in this study.71 In addition to canagliflozin 300 mg tablet daily, the 
intervention group will receive lifestyle modification education. This education will be 
identical to that given to the control group to ensure blinding of the participants and 
investigators.  
While González-Ortiz et al. found encouraging results after only 12 weeks of 
SGLT2i administration, the authors note that longer-term studies need to be performed to 
confirm the findings.67 Landmark studies of SGLT2is have administered treatment for 
close to 5 years, but all were able to find notable results after 52 weeks.60,61,64 In an effort 
to maintain both feasibility and reliability, the duration of the intervention for the 
proposed study will be 52 weeks. In this achievable time frame, we expect well-founded 
results that can translate to clinical practice.  
2.6.2 Choice of Control Group 
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 Most studies evaluating the potential benefit of SGLT2is as monotherapy, 
regardless of the study population, compare the drug class to either a placebo drug, 
another antidiabetic drug, or an intensive lifestyle intervention. None of these studies 
have compared the drug class to lifestyle modification education alone, which is what 
might typically be offered initially to nondiabetic adults with MetS. Such a control group 
is necessary to establish the efficacy of SGLT2is compared to current clinician practices.  
Bo et al. managed to compare the role of recommendation-based lifestyle 
intervention program given by trained professionals to unstructured advice given by 
family physicians (“usual care”) in the remission of MetS. This study demonstrated that 
usual care is insufficient to treat MetS, and alternative therapies are necessary.17   
Thus, our RCT will employ lifestyle modification education as our control for the 
purposes of comparing SGLT2is to the reality of standard treatment for MetS in 
nondiabetic adults. Modeled off of Bo et al.’s RCT, participants will receive the lifestyle 
modification education from our research team’s physicians once at the start of the 
intervention period, with no further material offered for the entirety of the 52 weeks.17 
This education will be identical to that given to the intervention group. The control group 
will also receive a placebo pill that appears identical to the canagliflozin 300 mg tablet to 
keep in accordance with a double-blinded clinical trial. This control group will serve to 
demonstrate whether there is a difference between an SGLT2i and actual everyday 
practice and help direct future clinical management.  
2.6.3 Study Population: Inclusion and Exclusion Criteria 
  The NCEP/ATPIII definition of MetS is the most widely accepted and utilized 
classification for diagnosis. When experts in the field discuss the implications of a MetS 
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diagnosis, the risk of progression to T2DM is frequently cited.2 This reported risk of 
progression to T2DM implies that those with MetS who would benefit considerably from 
an intervention are in a state of prediabetes (FPG 100-125 mg/dL). Therefore, adults 
(aged 18-65 years) meeting a modified NCEP/ATPIII definition of MetS will be recruited 
as the study population for our proposed RCT, where the modified definition is as 
follows: 
 Participants must have any three or more of the following: 
• IFG (FPG 100-125 mg/dL)  
• Abdominal obesity (waist circumference > 40 inches in men and > 35 
inches in women) 
• Blood pressure  135/85 mmHg 
• Triglycerides  150 mg/dL 
• HDL cholesterol < 40 mg/dL in men and < 50 mg/dL in women 
In addition to T2DM, other diseases to be excluded include type 1 diabetes 
mellitus, CVDs, chronic liver or kidney disease, and advanced cancer. These diseases, 
which require medications and specific diet and exercise recommendations, would likely 
bias the results of the study.17,67 In efficacy and safety studies of 300 mg canagliflozin, 
participants with moderate renal impairment (estimated glomerular filtration rate [eGFR] 
30-50 mL/min/1.73m2) experienced increases in serum potassium levels. This population 
may also be more susceptible to complications such as hypotension or acute kidney 
injury with canagliflozin at any dosage. Due to the increased potential for adverse events 
with moderate renal impairment and the 300 mg dose of canagliflozin used for this 
proposed study, those with an eGFR of <60 mL/min/1.73m2 will be excluded from the 
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study. Canagliflozin is contraindicated in dialysis patients, and thus dialysis patients will 
be excluded as well.58 
Elderly participants (>65 years) will be excluded to not only maintain consistency 
with several other relevant studies,17,67 but also to limit the number of adverse events. 
Due to its mechanism of action, canagliflozin has the ability to reduce intravascular 
volume. This process was shown to cause more adverse events (i.e. orthostatic 
hypotension, syncope, dehydration, etc.) in those >65 years more often than in younger 
individuals in 13 clinical trials of canagliflozin.58  
 While there is existing human data to speak to the effects of canagliflozin on the 
elderly, the same cannot be said for pregnant or breastfeeding women and breastfed 
infants. Any efficacy or safety data for these populations comes from animal studies.58 
Due to the lack of human evidence, pregnant and breastfeeding women will be excluded 
from the study. Further, any women of childbearing age must agree to use an acceptable 
birth control method. These include tubal ligation, transdermal patch, intrauterine 
device/system, oral, implantable, or injectable contraceptives, sexual abstinence, double 
barrier method, or vasectomy of partner. This requirement is adapted from the EMPA-
REG OUTCOME study.60 
 In accordance with the landmark CANVAS study, current or prior users of 
SGLT2is will be excluded from the study.61 All participants being SGLT2i-naïve allows 
the outcomes between participants to be more accurately compared.  
2.6.4 Primary and Secondary Outcomes  
Several studies investigating SGLT2is look at the drugs’ effects on the five 
abnormalities of MetS as distinct secondary outcomes.59,67 Despite the evidence of its 
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metabolic effects, there is no evidence supporting the use of canagliflozin as a single 
treatment for MetS. Therefore, remission of MetS will be the dichotomous primary 
outcome of this study.  
Many secondary outcomes will be measured in this study, including the five 
distinct metabolic abnormalities of MetS: fasting plasma glucose (mg/dL), waist 
circumference (inches), blood pressure (mmHg), triglyceride level (mg/dL), and HDL 
cholesterol (mg/dL). Evaluating these abnormalities separately will quantify the 
metabolic effects of canagliflozin 300 mg in nondiabetic adults after one year of 
treatment. It will also allow for the analysis of which improved metabolic abnormality 
contributes most to the remission of MetS. 
Additional secondary outcomes will include CRP level (mg/L), change in diet, 
change in exercise, insulin resistance, and hA1C. Numerous studies have linked elevated 
CRP levels with MetS, and there is evidence to support that elevated CRP levels 
contribute to an increased cardiovascular risk.72 In 2004, Yudkin et al. found strong 
associations between the CRP levels and metabolic abnormalities, including insulin 
resistance, blood pressure, low HDL, and triglycerides in nondiabetics with MetS.73 
There is limited evidence suggesting SGLT2is reduce CRP levels. One study conducted 
by Garvey et al. found a trend of decreasing CRP levels in participants with T2DM (on 
metformin) receiving canagliflozin 300 mg for 52 weeks; however, this trend was not 
statistically significant.74 Because there is a strong association between CRP levels and 
MetS, and there is currently insufficient evidence to ascertain a relationship between 
SGLT2is and CRP levels, CRP levels make for an important secondary outcome in 
establishing the effect of SGLT2is (in this case, canagliflozin) on MetS.  
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Change in diet and exercise over the 52-week intervention period are two 
variables that may influence the primary outcome of our proposed study, and thus they 
must be included as secondary outcomes to evaluate for a modifying effect. To monitor 
for changes in diet, participants will complete a Food Frequency Questionnaire (FFQ) on 
both the first and last day of the intervention period. The FFQ is a fixed list of foods and 
beverages with areas to indicate the usual frequency of consumption of specific portion 
sizes over a stated period of time.75 The FFQ to be used for this proposed study is the 
Diet History Questionnaire III (DHQ III) developed by the National Cancer Institute, 
which includes 135 food and beverage line items and 26 dietary supplement questions.76 
In 2003, the OPEN study evaluated the validity of the “Past Year with Portion Size” 
DHQ III and determined that underreporting is a significant problem.77 Because recall 
accuracy declines as the time between the reference period and the administration of a 
FFQ increases,78 the “Past Month with Portion Size” DHQ III will be administered in 
hopes of limiting measurement error and recall bias. The Healthy Eating Index-2015 
(HEI) is a data output of the “Past Month with Portion Size” DHQ III that measures 
alignment with the Dietary Guidelines for Americans, and it has demonstrated both 
construct validity and reliability for this purpose.79  
To monitor for changes in exercise, the Stanford 7-day Physical Activity Recall 
(PAR) self-report questionnaire will be used. Categories of activity included in this well-
studied questionnaire are sleep and moderate, hard, and very hard physical activity. 
Although this questionnaire is subject to recall and social desirability bias, it is cost 
effective and easy to administer among groups. In A Practical Guide to Measuring 
Physical Activity, Sylvia et al. reports that adults have adequate recall ability for a self-
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report questionnaire,80 and thus the Stanford 7-Day PAR should be sufficient in 
measuring our secondary variable. Energy expenditure, measured in kcal/kg/day, is a data 
output of the questionnaire, making the results of the questionnaires easily comparable 
amongst study participants. 
Seeing that insulin resistance is the leading mechanism proposed for the 
development of MetS, it is important to quantify this value and monitor changes in the 
participants.67 In our study, insulin resistance will be estimated using the modified 
homeostasis model assessment (HOMA-IR). HOMA-IR is a simple index based on 
fasting levels of glucose and insulin that has been validated for the estimation of insulin 
resistance. Simple indices assess hepatic insulin resistance (the chief contributor to the 
pre-diabetic state) more than they do peripheral insulin sensitivity, and is consequently 
unreliable for populations with uncontrolled T2DM or type 1 diabetes mellitus. While it 
has been argued that this method of assessment is a limitation of simple indices such as 
HOMA-IR,81 in the case of our proposed study it may actually serve as a strength, given 
that our population will include those in a pre-diabetic state.  
T2DM is a significant consequence of MetS, and therefore its risk and potential 
progression over time should be measured as a secondary outcome in our sample 
population. T2DM risk and progression is typically measured by hA1C as a percentage, 
and thus our study will do the same.82,83 
2.6.5 Monitoring of Side Effects and Adverse Events 
 In their 12-week RCT evaluating dapagliflozin for the remission of MetS, 
González-Ortíz et al. had participants record side effects in a diary and present the diary 
at monthly visits, where the investigator would inquire further if needed.67 Although the 
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intervention and primary outcome of González-Ortíz et al.’s study is most similar to those 
of the one being proposed, their method of identifying adverse events leaves room for 
error. For instance, it is unclear whether the participants were aware of which symptoms 
to be concerned about and document, or whether investigators conducted thorough 
physical exams and testing regardless of participants’ diary recordings. Consequently, it 
is possible some side effects or adverse events were missed. 
In a better effort to account for safety outcomes and adverse events, the three 
large phase 3 trials evaluating the effect of SGLT2is on cardiovascular outcomes had 
participants return for in-person follow-up appointments at pre-specified periods during 
the course of the studies.60,61,64 For example, the DECLARE study had participants 
follow-up every 6 months, while the CANVAS study had participants follow-up every 3 
months in the first year, and every 6 months thereafter (each study also conducted 
telephone follow-ups in between in-person visits).61,64 Because the proposed study will 
last for only 52 weeks, monitoring of side effects and adverse events will take place 
during in-person follow-ups every 3 months with telephone follow-up occurring every 
month, as modeled after the CANVAS study.61 Safety outcomes as previously mentioned 
in “Limitations of Sodium-Glucose Cotransporter 2 Inhibitors” will be followed 
throughout the course of this study.  
2.6.6 Confounding Variables  
 Due to the nature of RCTs, the effects of any variables related to both the 
exposure (canagliflozin) and the primary outcome (remission of MetS) should be reduced 
and likely insignificant. However, there are effect modifiers that have often been noted in 
relevant studies, including age, education level, smoking habits, alcohol consumption, 
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LDL levels, change in diet and exercise, and independent prescriptions for specific MetS 
abnormalities.6,66  
2.7 Conclusion 
 Existing literature backs the use of SGLT2is as a single drug catalyst for 
remission of MetS. To date, only one study has evaluated such a proposal, with the 
results being limited by a small sample size and short follow-up period. Due to its 
documented superiorities over other drugs in its class, canagliflozin is a sensible SGLT2i 
for further study. Remission of MetS is a logical primary outcome because the results 
could have additional implications for canagliflozin’s ability to prevent T2DM and CVD. 
Important secondary variables to consider include FPG, waist circumference, blood 
pressure, triglycerides, and HDL cholesterol, as well as CRP, HEI, energy expenditure, 
HOMA-IR, and hA1C. Important adverse events to monitor include number of genital 
mycotic infections and amputations, among others. These variables will not only provide 
further insight into the effect of canagliflozin on individual metabolic abnormalities, but 
also reveal potentially modifying effects on the primary outcome and further clarify the 




1. Samson SL, Garber AJ. Metabolic Syndrome. Endocrinology and Metabolism 
Clinics of North America. 2014;43(1):1-23. 
2. Huang PL. A comprehensive definition for metabolic syndrome. Disease models 
& mechanisms. 2009;2(5-6):231-237. 
3. Swarup S, Zeltser R. Metabolic Syndrome. In: StatPearls. Treasure Island (FL): 
StatPearls Publishing LLC.; 2019. 
4. Ford ES, Li C, Sattar N. Metabolic syndrome and incident diabetes: current state 
of the evidence. Diabetes care. 2008;31(9):1898-1904. 
5. Ninomiya John K, L’Italien G, Criqui Michael H, Whyte Joanna L, Gamst A, 
Chen Roland S. Association of the Metabolic Syndrome With History of 
Myocardial Infarction and Stroke in the Third National Health and Nutrition 
Examination Survey. Circulation. 2004;109(1):42-46. 
6. Lakka H-M, Laaksonen DE, Lakka TA, et al. The Metabolic Syndrome and Total 
and Cardiovascular Disease Mortality in Middle-aged Men. Jama. 
2002;288(21):2709-2716. 
7. Benjamin Emelia J, Blaha Michael J, Chiuve Stephanie E, et al. Heart Disease 
and Stroke Statistics—2017 Update: A Report From the American Heart 
Association. Circulation. 2017;135(10):e146-e603. 
8. Huh JH, Ahn SG, Kim YI, et al. Impact of Longitudinal Changes in Metabolic 
Syndrome Status over 2 Years on 10-Year Incident Diabetes Mellitus. Diabetes & 
metabolism journal. 2019;43(4):530-538. 
9. Park S, Lee S, Kim Y, et al. Altered Risk for Cardiovascular Events With 
Changes in the Metabolic Syndrome Status: A Nationwide Population-Based 
Study of Approximately 10 Million Persons. Annals of internal medicine. 
2019;171(12):875-884. 
10. Oladejo AO. Overview of the metabolic syndrome; an emerging pandemic of 
public health significance. Ann Ib Postgrad Med. 2011;9(2):78-82. 
11. Armstrong C. Practice Guidelines: AHA and NHLBI Review Diagnosis and 
Management of the Metabolic Syndrome. American Academy of Family 
Physicians 2006;74. 
12. Bassi N, Karagodin I, Wang S, et al. Lifestyle Modification for Metabolic 
Syndrome: A Systematic Review. The American journal of medicine. 
2014;127(12):1242.e1241-1242.e1210. 
13. Grundy SM. Metabolic Syndrome: Connecting and Reconciling Cardiovascular 
and Diabetes Worlds. Journal of the American College of Cardiology. 
2006;47(6):1093-1100. 
14. Han TS, Lean ME. A clinical perspective of obesity, metabolic syndrome and 
cardiovascular disease. JRSM Cardiovasc Dis. 2016;5:2048004016633371-
2048004016633371. 
15. Stone NJ, Saxon D. Approach to Treatment of the Patient with Metabolic 
Syndrome: Lifestyle Therapy. The American Journal of Cardiology. 2005;96(4, 
Supplement):15-21. 
 33 
16. Pettman TL, Misan GMH, Owen K, et al. Self-management for obesity and 
cardio-metabolic fitness: Description and evaluation of the lifestyle modification 
program of a randomised controlled trial. International Journal of Behavioral 
Nutrition and Physical Activity. 2008;5(1):53. 
17. Bo S, Ciccone G, Baldi C, et al. Effectiveness of a Lifestyle Intervention on 
Metabolic Syndrome. A Randomized Controlled Trial. Journal of General 
Internal Medicine. 2007;22(12):1695-1703. 
18. Robert M. Kaplan PDaHJS, M.D., Ph.D. Compliance in Medical Care: 
Reconsideration of Self-Predictions. Annals of Behavioral Medicine. 1990;12. 
19. Group TDPPR. Reduction in the Incidence of Type 2 Diabetes with Lifestyle 
Intervention or Metformin. New England Journal of Medicine. 2002;346(6):393-
403. 
20. Wing RR, Phelan S. Long-term weight loss maintenance. The American Journal 
of Clinical Nutrition. 2005;82(1):222S-225S. 
21. Tankova T. Current indications for metformin therapy. Rom J Intern Med. 
2003;41(3):215-225. 
22. Grundy SM. Drug therapy of the metabolic syndrome: minimizing the emerging 
crisis in polypharmacy. Nature Reviews Drug Discovery. 2006;5(4):295-309. 
23. Rollason V, Vogt N. Reduction of Polypharmacy in the Elderly. Drugs & aging. 
2003;20(11):817-832. 
24. Orchard TJ, Temprosa M, Goldberg R, et al. The Effect of Metformin and 
Intensive Lifestyle Intervention on the Metabolic Syndrome: The Diabetes 
Prevention Program Randomized Trial. Annals of internal medicine. 
2005;142(8):611-619. 
25. Mosley JF, 2nd, Smith L, Everton E, Fellner C. Sodium-Glucose Linked 
Transporter 2 (SGLT2) Inhibitors in the Management Of Type-2 Diabetes: A 
Drug Class Overview. P T. 2015;40(7):451-462. 
26. Ansary TM, Nakano D, Nishiyama A. Diuretic Effects of Sodium Glucose 
Cotransporter 2 Inhibitors and Their Influence on the Renin-Angiotensin System. 
International journal of molecular sciences. 2019;20(3):629. 
27. Steen O, Goldenberg RM. The Role of Sodium-Glucose Cotransporter 2 
Inhibitors in the Management of Type 2 Diabetes. Canadian journal of diabetes. 
2017;41(5):517-523. 
28. Strojek K, Yoon KH, Hruba V, Elze M, Langkilde AM, Parikh S. Effect of 
dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic 
control with glimepiride: a randomized, 24-week, double-blind, placebo-
controlled trial. Diabetes, Obesity and Metabolism. 2011;13(10):928-938. 
29. Rosenstock J, Jelaska A, Frappin G, et al. Improved Glucose Control With 
Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With 
Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese 
Inadequately Controlled Type 2 Diabetes. Diabetes care. 2014;37(7):1815-1823. 
30. Kovacs CS, Seshiah V, Swallow R, et al. Empagliflozin improves glycaemic and 
weight control as add-on therapy to pioglitazone or pioglitazone plus metformin 
in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. 
Diabetes, Obesity and Metabolism. 2014;16(2):147-158. 
 34 
31. Häring H-U, Merker L, Seewaldt-Becker E, et al. Empagliflozin as Add-on to 
Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes. A 24-week, 
randomized, double-blind, placebo-controlled trial. 2013;36(11):3396-3404. 
32. Rosenstock J, Seman LJ, Jelaska A, et al. Efficacy and safety of empagliflozin, a 
sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 
2 diabetes with mild hyperglycaemia. Diabetes, Obesity and Metabolism. 
2013;15(12):1154-1160. 
33. Kadowaki T, Haneda M, Inagaki N, et al. Empagliflozin Monotherapy in 
Japanese Patients with Type 2 Diabetes Mellitus: a Randomized, 12-Week, 
Double-Blind, Placebo-Controlled, Phase II Trial. Advances in Therapy. 
2014;31(6):621-638. 
34. Ferrannini E, Seman L, Seewaldt-Becker E, Hantel S, Pinnetti S, Woerle HJ. A 
Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor 
empagliflozin in patients with type 2 diabetes. Diabetes, Obesity and Metabolism. 
2013;15(8):721-728. 
35. Kanada S, Koiwai K, Taniguchi A, Sarashina A, Seman L, Woerle HJ. 
Pharmacokinetics, pharmacodynamics, safety and tolerability of 4 weeks' 
treatment with empagliflozin in Japanese patients with type 2 diabetes mellitus. 
Journal of Diabetes Investigation. 2013;4(6):613-617. 
36. Jabbour SA, Hardy E, Sugg J, Parikh, Shamik. Dapagliflozin Is Effective as Add-
on Therapy to Sitagliptin With or Without Metformin: A 24-Week, Multicenter, 
Randomized, Double-Blind, Placebo-Controlled Study. Diabetes care. 
2014;37(3):740-750. 
37. Rosenstock J, Vico M, Wei L, Salsali A, List JF. Effects of Dapagliflozin, an 
SGLT2 Inhibitor, on HbA<sub>1c</sub>, Body Weight, and Hypoglycemia Risk 
in Patients With Type 2 Diabetes Inadequately Controlled on Pioglitazone 
Monotherapy. Diabetes care. 2012;35(7):1473-1478. 
38. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in 
patients with type 2 diabetes who have inadequate glycaemic control with 
metformin: a randomised, double-blind, placebo-controlled trial. The Lancet. 
2010;375(9733):2223-2233. 
39. Bailey CJ, Iqbal N, T'joen C, List JF. Dapagliflozin monotherapy in drug-naïve 
patients with diabetes: a randomized-controlled trial of low-dose range. Diabetes, 
Obesity and Metabolism. 2012;14(10):951-959. 
40. Kaku K, Kiyosue A, Inoue S, et al. Efficacy and safety of dapagliflozin 
monotherapy in Japanese patients with type 2 diabetes inadequately controlled by 
diet and exercise. Diabetes, Obesity and Metabolism. 2014;16(11):1102-1110. 
41. Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin Monotherapy 
in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and 
Exercise. A randomized, double-blind, placebo-controlled, phase 3 trial. 
2010;33(10):2217-2224. 
42. Forst T, Guthrie R, Goldenberg R, et al. Efficacy and safety of canagliflozin over 
52 weeks in patients with type 2 diabetes on background metformin and 
pioglitazone. Diabetes, Obesity and Metabolism. 2014;16(5):467-477. 
 35 
43. Wilding JPH, Charpentier G, Hollander P, et al. Efficacy and safety of 
canagliflozin in patients with type 2 diabetes mellitus inadequately controlled 
with metformin and sulphonylurea: a randomised trial. International journal of 
clinical practice. 2013;67(12):1267-1282. 
44. Lavalle-González FJ, Januszewicz A, Davidson J, et al. Efficacy and safety of 
canagliflozin compared with placebo and sitagliptin in patients with type 2 
diabetes on background metformin monotherapy: a randomised trial. 
Diabetologia. 2013;56(12):2582-2592. 
45. Stenlöf K, Cefalu WT, Kim K-A, et al. Efficacy and safety of canagliflozin 
monotherapy in subjects with type 2 diabetes mellitus inadequately controlled 
with diet and exercise. Diabetes, Obesity and Metabolism. 2013;15(4):372-382. 
46. Abdul-Ghani M, Al Jobori H, Daniele G, et al. Inhibition of Renal Sodium–
Glucose Cotransport With Empagliflozin Lowers Fasting Plasma Glucose and 
Improves β-Cell Function in Subjects With Impaired Fasting Glucose. Diabetes. 
2017;66(9):2495. 
47. Stenlöf K, Cefalu WT, Kim K-A, et al. Long-term efficacy and safety of 
canagliflozin monotherapy in patients with type 2 diabetes inadequately 
controlled with diet and exercise: findings from the 52-week CANTATA-M 
study. Current medical research and opinion. 2014;30(2):163-175. 
48. Scheen AJ. Pharmacokinetic and pharmacodynamic profile of empagliflozin, a 
sodium glucose co-transporter 2 inhibitor. Clin Pharmacokinet. 2014;53(3):213-
225. 
49. Pinto LC, Rados DV, Remonti LR, Kramer CK, Leitao CB, Gross JL. Efficacy of 
SGLT2 inhibitors in glycemic control, weight loss and blood pressure reduction: a 
systematic review and meta-analysis. Diabetology & metabolic syndrome. 
2015;7(Suppl 1):A58-A58. 
50. Bays HE, Weinstein R, Law G, Canovatchel W. Canagliflozin: effects in 
overweight and obese subjects without diabetes mellitus. Obesity (Silver Spring). 
2014;22(4):1042-1049. 
51. Rosenwasser RF, Sultan S, Sutton D, Choksi R, Epstein BJ. SGLT-2 inhibitors 
and their potential in the treatment of diabetes. Diabetes, Metabolic Syndrome 
and Obesity: Targets and Therapy. 2013;6:453-467. 
52. Tahrani AA, Barnett AH, Bailey CJ. SGLT inhibitors in management of diabetes. 
The Lancet Diabetes & Endocrinology. 2013;1(2):140-151. 
53. Iemitsu K, Iizuka T, Takihata M, et al. Factors Influencing Changes in 
Hemoglobin A1c and Body Weight During Treatment of Type 2 Diabetes With 
Ipragliflozin: Interim Analysis of the ASSIGN-K Study. Journal of clinical 
medicine research. 2016;8(5):373-378. 
54. Kawata T, Iizuka T, Iemitsu K, et al. Ipragliflozin Improves Glycemic Control 
and Decreases Body Fat in Patients With Type 2 Diabetes Mellitus. Journal of 
clinical medicine research. 2017;9(7):586-595. 
55. Lee PC, Ganguly S, Goh S-Y. Weight loss associated with sodium-glucose 
cotransporter-2 inhibition: a review of evidence and underlying mechanisms. 
Obesity Reviews. 2018;19(12):1630-1641. 
 36 
56. Bolinder J, Ljunggren Ö, Kullberg J, et al. Effects of Dapagliflozin on Body 
Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients 
with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin. 
The Journal of Clinical Endocrinology & Metabolism. 2012;97(3):1020-1031. 
57. Ali A, Bain S, Hicks D, et al. SGLT2 Inhibitors: Cardiovascular Benefits Beyond 
HbA1c—Translating Evidence into Practice. Diabetes Therapy. 2019. 
58. Inc. JP. INVOKANA™ (canagliflozin) tablets, for oral use [prescribing 
information]. 2013. 
59. Zaccardi F, Webb DR, Htike ZZ, Youssef D, Khunti K, Davies MJ. Efficacy and 
safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: 
systematic review and network meta-analysis. Diabetes, Obesity and Metabolism. 
2016;18(8):783-794. 
60. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, 
and Mortality in Type 2 Diabetes. New England Journal of Medicine. 
2015;373(22):2117-2128. 
61. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and 
Renal Events in Type 2 Diabetes. New England Journal of Medicine. 
2017;377(7):644-657. 
62. Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium–Glucose 
Cotransporter 2 Inhibitors for Type 2 Diabetes: A Systematic Review and Meta-
analysis. Annals of internal medicine. 2013;159(4):262-274. 
63. Fitchett D. A safety update on sodium glucose co-transporter 2 inhibitors. 
Diabetes, Obesity and Metabolism. 2019;21(S2):34-42. 
64. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and Cardiovascular Outcomes 
in Type 2 Diabetes. New England Journal of Medicine. 2018;380(4):347-357. 
65. U.S. Food and Drug Administration. Drug Safety Communication: FDA warns 
that SGLT2 inhibitors for diabetes may result in a serious condition of too much 
acid in the blood; . In. 
66. den Engelsen C, Gorter KJ, Salomé PL, van den Donk M, Rutten GE. Remission 
of screen-detected metabolic syndrome and its determinants: an observational 
study. BMC Public Health. 2012;12:778-778. 
67. Gonzalez-Ortiz M, Mendez-Del Villar M, Martinez-Abundis E, Ramirez-
Rodriguez AM. Effect of dapagliflozin administration on metabolic syndrome, 
insulin sensitivity, and insulin secretion. Minerva Endocrinol. 2018;43(3):229-
235. 
68. Tentolouris A, Vlachakis P, Tzeravini E, Eleftheriadou I, Tentolouris N. SGLT2 
Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects. Int J 
Environ Res Public Health. 2019;16(16):2965. 
69. Storgaard H, Gluud LL, Bennett C, et al. Benefits and Harms of Sodium-Glucose 
Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic 
Review and Meta-Analysis. PloS one. 2016;11(11):e0166125-e0166125. 
70. Zhang X-L, Zhu Q-Q, Chen Y-H, et al. Cardiovascular Safety, Long-Term 
Noncardiovascular Safety, and Efficacy of Sodium-Glucose Cotransporter 2 
Inhibitors in Patients With Type 2 Diabetes Mellitus: A Systemic Review and 
 37 
Meta-Analysis With Trial Sequential Analysis. J Am Heart Assoc. 
2018;7(2):e007165. 
71. Shyangdan DS, Uthman OA, Waugh N. SGLT-2 receptor inhibitors for treating 
patients with type 2 diabetes mellitus: a systematic review and network meta-
analysis. BMJ open. 2016;6(2):e009417-e009417. 
72. Devaraj S, Singh U, Jialal I. Human C-reactive protein and the metabolic 
syndrome. Curr Opin Lipidol. 2009;20(3):182-189. 
73. Yudkin JS, Juhan-Vague I, Hawe E, et al. Low-grade inflammation may play a 
role in the etiology of the metabolic syndrome in patients with coronary heart 
disease: the HIFMECH study. Metabolism: clinical and experimental. 
2004;53(7):852-857. 
74. Garvey WT, Van Gaal L, Leiter LA, et al. Effects of canagliflozin versus 
glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes. 
Metabolism: clinical and experimental. 2018;85:32-37. 
75. National Cancer Institute. Dietary Assessment Primer. 
https://dietassessmentprimer.cancer.gov/profiles/questionnaire/index.html. 
Accessed. 
76. National Cancer Institute. Diet History Questionnaire. 
https://epi.grants.cancer.gov/dhq3/index.html. Published 2019. Updated June 28 
2019. Accessed. 
77. Subar AF, Kipnis V, Troiano RP, et al. Using Intake Biomarkers to Evaluate the 
Extent of Dietary Misreporting in a Large Sample of Adults: The OPEN Study. 
American Journal of Epidemiology. 2003;158(1):1-13. 
78. Zuniga K, McAuley E. Considerations in selection of diet assessment methods for 
examining the effect of nutrition on cognition. J Nutr Health Aging. 
2015;19(3):333-340. 
79. Reedy J, Lerman JL, Krebs-Smith SM, et al. Evaluation of the Healthy Eating 
Index-2015. J Acad Nutr Diet. 2018;118(9):1622-1633. 
80. Sylvia LG, Bernstein EE, Hubbard JL, Keating L, Anderson EJ. Practical guide to 
measuring physical activity. J Acad Nutr Diet. 2014;114(2):199-208. 
81. Borai A, Livingstone C, Kaddam I, Ferns G. Selection of the appropriate method 
for the assessment of insulin resistance. BMC Med Res Methodol. 2011;11:158-
158. 
82. Clinic M. A1C test. https://www.mayoclinic.org/tests-procedures/a1c-
test/about/pac-20384643. Published 2018. Accessed. 
83. List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-Glucose Cotransport 
Inhibition With Dapagliflozin in Type 2 Diabetes. Diabetes care. 2009;32(4):650. 
 
 38 
Chapter 3 – Study Methods 
 
3.1 Study Design 
 Our study will be a 52-week, multi-center, double-blinded, placebo-controlled 
randomized clinical trial.  
3.2 Study Population and Sampling 
 The study population will include adults aged 18-65 years who meet our modified 
NCEP/ATPIII definition of metabolic syndrome (MetS). Both English- and Spanish-
speakers will be included. PCPs in the greater New Haven area will be asked to identify 
eligible patients meeting our inclusion criteria and exclusion criteria and refer them to our 
team. Recruitment will take place over an 11-month period to ensure an adequate pool 
from which to select our final sample. This sampling method is partially biased by the 
initial convenience sampling of those who visit a provider. Given the risks associated 
with canagliflozin, the SGLT2i is most safely used in those who have access to and make 
use of regular monitoring, and thus this limitation is reasonable. Participants selected will 
undergo a final screening, including blood tests and a physical exam, conducted by team 
members to ensure all meet criteria as delineated below. If criteria are met and informed 
consent is signed, this final screening will serve as the participants’ baseline values and 
will mark the beginning of the intervention period.  
3.3 Inclusion Criteria 
 In order to be considered for participation, subjects must meet our modified 
NCEP/ATPIII definition of MetS: 
• IFG (FPG 100-125 mg/dL)  
 39 
• Abdominal obesity (waist circumference > 40 inches in men and > 35 inches 
in women) 
• Blood pressure  135/85 mmHg 
• Triglycerides  150 mg/dL 
•  HDL cholesterol < 40 mg/dL in men and < 50 mg/dL in women 
These criteria will be confirmed with blood testing and a physical exam prior to the start 
of the study.  
3.4 Exclusion Criteria 
In addition to T2DM (defined as FPG >125 mg/dL), subjects diagnosed with type 
1 diabetes mellitus, CVD, chronic liver or kidney disease (eGFR <60 mL/min/1.73m2), 
and advanced cancer will be excluded from the study. The reason for the exclusion of 
these diseases stems from their specific diet and exercise recommendations that could 
potentially interfere with the results of the study. Elderly patients (>65 years), pregnant 
and breastfeeding women will be excluded to reduce the risk of adverse events. Any 
women of childbearing age not agreeable to acceptable birth control will be excluded. 
Acceptable forms of birth control include tubal ligation, transdermal patch, intrauterine 
device/system, oral, implantable, or injectable contraceptives, sexual abstinence, double 
barrier method, or vasectomy of partner. Current or prior users of SGLT2is will be 
excluded in order to compare the outcomes of the study more accurately. Non-English 
and non-Spanish speakers will be excluded.  
3.5 Subject Protection and Confidentiality 
 Institutional Review Board (IRB) approval will be obtained prior to recruitment to 
ensure the personal information of all participants is kept private and confidential during 
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the recruitment, screening, and conduct of the research as appropriate. Keeping in 
accordance with IRB’s policy will establish the trust of our participants and facilitate 
their willingness to share information. All participants will be required to sign a written 
informed consent, as detailed by Yale University’s IRB Policy 200. Contents of the 
informed consent will be available in both English and Spanish, and will include the 
following elements: an explanation of the purpose of the research, duration of 
participation, description of procedures, foreseeable risks and benefits, methods of 
protecting confidentiality, limits to confidentiality, a statement that participants may 
withdraw at any time without explanation, and more. All participants will be informed 
should significant new findings develop during the course of the research that may affect 
their willingness to proceed. Participants will be made aware that, if necessary, the 
principal investigators may terminate their involvement at any time. Contact information 
will be provided should participants have any comments, questions, or concerns. See 
Appendix A for a sample consent form.  
 In conformity with IRB approval requirements, our study will comply with all 
relevant privacy standards and regulations as specified by the Health Insurance 
Portability and Accountability Act (HIPAA). This includes the method of blinding both 
investigators and participants, as well as the creation, collection, and storage of health 
information.  
3.6 Recruitment 
 PCPs in the greater New Haven area will be asked to recruit patients from their 
outpatient clinics and refer them to the research team. Recruits will receive a small 
information flyer from their PCPs describing relevant study details, contact information, 
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and compensation for participations ($100 at each in-person follow-up visit and $200 at 
the final visit, totaling $500). Participants will begin the study as they are being recruited. 
A sample information flyer for recruitment is included in Appendix B.  
3.7 Study Variables and Measures 
3.7.1 Independent Variable: Intervention and Placebo Control 
 The intervention group will receive one canagliflozin 300 mg tablet to be taken 
once every morning for 52 weeks. Similarly, the active control group will receive a 
placebo tablet to be taken once every morning for 52 weeks. Both the intervention and 
active control groups will receive lifestyle modification education one time from a 
research team physician at the start of the 52 weeks. Participants will receive 90 tablets at 
a time and are expected to attend an in-person follow-up visit with an investigator every 3 
months for a refill and debrief. Monthly telephone follow-ups will also occur in between 
the in-person visits to address any comments, questions or concerns.  
3.7.2 Dependent Variable: Primary and Secondary Outcomes 
 The primary outcome of this study is remission of MetS after 52 weeks, with 
remission of MetS being defined as two or less of the five metabolic abnormalities as 
previously described. This is a dichotomous variable, with the two categories being ‘yes’ 
or ‘no.’  
 The secondary outcomes of this study will include the five distinct measures of 
MetS – FPG (mg/dL), waist circumference (inches), blood pressure (mmHg), triglyceride 
level (mg/dL), and HDL level (mg/dL) – operationalized as within-person changes in 
medians between groups. Additional secondary outcomes will include within-person 
changes in median CRP level (mg/L), median HOMA-IR (U/mL x mg/dL), and median 
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hA1C (%) between groups. Diet will be measured by within-person changes in median 
HEI calculated from the “Past Month with Portion Size” DHQ III, and exercise will be 
measured by within-person changes in median energy expenditure (kcal/kg/day) 
calculated from the Stanford 7-day PAR.  
3.8 Blinding of Intervention and Outcome 
 To ensure that the principal investigators are blinded, control and intervention 
groups will be designated with either an ‘A’ or a ‘B’ for the duration of the study as well 
as the analysis. Participants will also be blinded to their respective groups by receiving 
identically appearing pills and lifestyle modification education. To blind the outcome of 
the study, analysis will occur before groups ‘A’ and ‘B’ are revealed as either 
intervention or control.  
3.9 Assignment to Intervention 
 Using computer-generated randomization, participants will be randomized into 
their respective groups labeled ‘A’ and ‘B’ in a 1:1 ratio.  
3.10 Data Collection 
Various methods for data collection will be utilized during this study. First, 
participating subjects will undergo blood testing and a physical examination at the start of 
the study to establish baseline values that both define our primary outcome and serve as 
individual secondary outcomes: FPG, waist circumference, blood pressure, triglycerides, 
and HDL cholesterol. Other secondary outcomes requiring blood testing, which include 
CRP levels, HOMA-IR, and hA1C will also be collected at this time. As for assessment 
of diet and exercise practices, participants will be expected to complete the “Past Month 
with Portion Size” DHQ III online, and the Stanford 7-Day PAR questionnaire will be 
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administered by a research team physician at the start of the study. A link to an example 
of the “Past Month with Portion Size” DHQIII can be found in Appendix C. A copy of 
the Stanford 7-Day PAR and a link to its protocol can be found in Appendix D. Pre-
menopausal women will also receive a pregnancy test. These same measures, with the 
exception of the diet and exercise questionnaires, will be tested and collected at each in-
person follow-up (every 3 months) and at the end of the 52-week intervention. The diet 
and exercise questionnaires will only be collected at the first and last visits. 
 Data on adverse events will be collected every 3 months at in-person follow-up 
visits. At these visits, a research team physician will conduct a thorough interview and 
physical examination to identify signs and symptoms that may be consistent with side 
effects or adverse events. Monthly telephone follow-ups will occur in order to maintain 
communication regarding any questions or concerns (such as side effects/adverse events) 
that may arise between the in-person visits. Participants will be encouraged, but not 
required, to keep track of any signs or symptoms in a daily diary so nothing is missed. All 
participants will have the contact information of the research team and will be 
encouraged to reach out should there be any questions or concerns. This information will 
be documented and analyzed at the end of the 52-week intervention period.  
3.11 Adherence 
Adherence to the canagliflozin 300mg/placebo tablets will be confirmed at the in-
person follow-up visits by method of pill counting and self-report.  
3.12 Sample Size  
The calculation for our sample size is adapted from that of Bo et. al,1 who’s study 
also aimed to find the difference in the proportion of MetS between two groups after one 
 44 
year. In the calculation of their sample size, Bo et. al. assumed an absolute difference in 
effect of 15% between their control group (unstructured lifestyle education) and their 
intervention group (detailed written and verbal individualized recommendations from 
trained professionals). The results of their study revealed that 9.1% of the control group 
no longer had MetS (defined by the NCEP/ATPIII criteria) at the end of the one-year 
study. To calculate our sample size, we used 9.1% as the estimated incidence proportion 
of remission we expect to see in our own control group, and used an absolute effect size 
of 15% to come to a predicted incidence proportion of remission of 24.1% in our 
intervention group. The sample size has also been calculated as a two-tailed test, using a 
power of 80% and an alpha of 0.05. These assumptions have led to a sample size of 190, 
as calculated by Power and Precision Version 4.0.BioStat, Englewood NJ. This means 
that, with 190 participants, 80% of studies would be expected to generate a significant 
effect that would reject the null hypothesis. Since we will assume a 15% loss to follow-
up, our final sample size will be 228. Because Bo et. al.’s intervention group was 
nonpharmacologic, we might actually find an even larger effect size in our study. Our 
sample size calculation is conservative in this way. The full sample size calculation is 
included in Appendix E.  
3.13 Analysis 
 Variables to describe the population will include age, sex, smoking status, alcohol 
consumption, body mass index (BMI) and other baseline laboratory and clinical values 
(see Table 1 below). Analysis will be performed under both the intention-to-treat and per-
protocol methods. Results will be statistically significant if p≤ 0.05. The Chi-squared 
statistical test will be used to analyze the dichotomous primary outcome (remission of 
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MetS: yes or no). The results of the primary outcome will be presented in Table 2. With 
regard to the secondary variables, all will be represented by a median and will be 
analyzed by the Wilcoxon Rank Sum test (Mann-Whitney U test). Such variables include 
within-person changes in median FPG (mg/dL), waist circumference (inches), blood 
pressure (mmHg), triglycerides (mg/dL), HDL cholesterol (mg/dL), CRP (mg/L), 
HOMA-IR (U/mL x mg/dL), hA1C (%), HEI, and energy expenditure (kcal/kg/day) 
between groups.  
 
Table 1: Clinical and Laboratory Baseline Characteristics of the Participants 
Characteristics Intervention Group Control Group 
Age, y   
Sex 
   Female 
   Male 
  
Smoking Status 
   Non-smoker 
   Current Smoker 
  
Alcohol Intake, g/day   
Height, m   
Weight, kg   
BMI, kg/m2   
FPG, mg/dL   
Waist circumference, in.   
Systolic blood pressure, mmHg   
Diastolic blood pressure, mmHg   
Triglycerides, mg/dL   
 46 
HDL cholesterol, mg/dL   
CRP Level, mg/L   
HOMA-IR, U/mL x mg/dL   
hA1C, %   
HEI    
Energy Expenditure, kcal/kg/day   
Data are n (%) or medians (25th percentile, 75th percentile) 
Table 2: Results of the Primary Outcome for the Proposed Study 
 Remission of MetS (n) No Remission of MetS (n) Total (n) 
Intervention    
Control    
Total   228 
 
3.14 Timeline and Resources 
 Two years will be required to complete the recruitment (11 months) and 
intervention periods (12 months) of this study (1 month buffer period). After a participant 
has been recruited, he/she will undergo a final screening to determine eligibility. At this 
final screening, the research team physicians will ensure every participant meets the 
inclusion and exclusion criteria and has signed the informed consent. This will also be the 
time that baseline values (lab data, physical examination data, questionnaire data, and 
pregnancy test if applicable) are collected and the intervention period begins. Eligible 
patients will then receive lifestyle modification education as provided by one of the 
research team physicians, as well as a 90-day supply of either the canagliflozin 300mg or 
control tablets.  
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 Every 3 months, the participants are expected back in the office for another 
physical exam and lab data collection, as well as an adherence assessment. At this time 
they will also receive their next 90-day supply of tablets, as well as their $100 
incremental compensation. Telephone follow-up will occur monthly to address any 
comments, questions or concerns. At the last visit, they will receive their final $200 for 
completing the study. This is also when final physical exam, questionnaire, and lab data 
collection for analysis will occur. Analysis is estimated to take about 6 months after all 
participants have completed the 12-month intervention period.   
 The study will be conducted at the Church Street Research Unit (CSRU). This 
facility can be rented as needed at low cost, offers six physical examination rooms, 
provides access to core lab services, and is staffed with a full-time nurse and a bilingual 
medical assistant. The hours of operation are flexible, making it simple for our 
participants to schedule appointments.  
Personnel required for the study include 2 managerial team members, 10 research 
team physicians that speak both English and Spanish, as well as 10 research assistants for 
data input and analysis. The research team physicians will be in charge of conducting the 
in-person visits and telephone follow-ups, confirming adherence by pill counting, 
collecting questionnaire data, and ordering labs. The full-time nurse staffed by CSRU 
will collect blood work from participants. In addition to office space and personnel 
salaries, the budget will include the cost of lab testing, printing small recruitment flyers, 
and compensation for participants. Janssen Pharmaceuticals, Inc will be approached and 
asked to provide canagliflozin 300 mg/placebo tablets for study participants free of 
charge, as well as any additional funding support the company can provide.  
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Chapter 4 – Conclusion 
 MetS is a critical risk factor for the development of T2DM and CVD, two of the 
leading causes of death and disability in the US.1 Currently, lifestyle modification 
education is the primary treatment, but 1 in 2 people do not adhere to the 
recommendations.2 Nonadherence for this population eventually results in multiple drug 
prescriptions to target each individual MetS risk factor,3 but this presents new problems 
of increased costs, decreased compliance, and adverse drug reactions.4,5 Such difficulties 
with current treatment options for MetS justifies a search for a better solution. SGLT2is 
are novel oral antidiabetic agents that have been shown to target all 5 metabolic 
abnormalities of MetS. Thus, SGLT2is have the potential to allow for remission of MetS 
and to reduce the rate of progression to T2DM and CVD as a single pharmacologic 
therapy.6 So far, there has been no RCT in the US to evaluate such potential. Hence, the 
aim of the proposed study is to establish a difference between canagliflozin as an adjunct 
to lifestyle modification education versus lifestyle medication education alone for the 
treatment of MetS in nondiabetic adults.  Results of this study will elucidate 
canagliflozin’s role in the remission of MetS and in the prevention of T2DM and CVD.  
4.1 Advantages 
 
 Advantages of the proposed study include its RCT study design. RCTs help to 
strengthen internal validity by random allocation of the intervention and control groups. 
In theory, this will ensure equal characteristics of the intervention and control groups to 
avoid the influence of confounding factors and minimize allocation bias. The utilization 
of double blinding in this study also minimizes potential information bias. The purpose of 
including both English- and Spanish-speakers in the proposed study is to maximize 
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external validity and reach wider populations that may benefit from canagliflozin as a 
treatment for MetS. This serves as an advantage by making the results of our study more 
applicable and relevant.  
4.2 Disadvantages 
 Despite the numerous advantages of the proposed study, there are several 
disadvantages that must be considered as well. First, the location of the study will be 
limited to the greater New Haven area, which will limit the generalizability of the results. 
Secondly, the RCT study design itself requires trust in the participants to comply with the 
intervention and placebo treatments. Noncompliance from either of these groups could 
threaten the validity and reliability of the study results. In anticipation for potential 
noncompliance, the participants will receive a total of $500 compensation for completion 
of the study, to be given in increments at each in-person follow-up visit. This will 
hopefully serve as a motivator to take the intervention/placebo drug as prescribed and 
prevent loss to follow-up. However, as a study with a moderately large sample 
population, this compensation for each participant becomes costly. Adding to this 
expense is the salary for all personnel, office space rent, lab testing, canagliflozin and 
placebo tablets, and other expenditures that make the proposed study a costly one.  
 In terms of our definition of MetS, it could be argued that restricting the criteria to 
a FPG of 100-125 mg/dL rather than 100 mg/dL will limit the study results. However, 
given that one of our study aims is to prevent the progression of MetS to T2DM with 
canagliflozin, this limitation is acceptable. 
Another disadvantage of the proposed study is that our intervention group will 
receive canagliflozin 300 mg tablets, whereas in clinical practice they would be started on 
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100 mg first.7 Further, our intervention period is limited to just 52 weeks in length while 
other large clinical trials evaluating the effects of SGLT2is followed participants for an 
average of 3-4 years.8-10 Our relatively short intervention period will limit us from 
understanding how long canagliflozin would be effective in our study population.  
4.3 Clinical and/or Public Health Significance 
As a predictor for the development of costly and burdensome chronic diseases, 
MetS is certainly a syndrome to be targeted for effective treatment. With current 
treatment strategies proving unsuccessful due to nonadherence and noncompliance, a 
search for a novel treatment approach that is easy to maintain is warranted. The proposed 
study offers a potential solution with canagliflozin – a once-a-day tablet that has been 
shown to target all five components of the syndrome.6 
If canagliflozin 300 mg plus lifestyle modification education is shown to have a 
significant benefit over lifestyle modification education alone for the remission of MetS 
in nondiabetic adults, it would be reasonable to consider the medication for use in clinical 
practice. Such results may lead to a slowed progression of MetS, a syndrome which 
affects over a third of the US adult population,11 to T2DM and CVD. Such results would 
also speak to the inefficacy of lifestyle modification education alone and may prompt 
revision to current strategies.  
 If the results were to suggest that lifestyle modification education alone has a 
significant benefit over the intervention for the remission of MetS, or suggest no 
difference at all, it may be wise to consider an alternative novel treatment, or to improve 
the current treatments available.  
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Regardless of the outcome, the proposed study has significant implications for the 
future treatment of MetS. It is also likely that the results could have a ripple effect on not 
only the health complications of the syndrome, but also the financial toll the syndrome 
places on the economy.  
4.4 Future Directions 
Given the limitations of this study, there are several directions for future clinical 
research to explore. To start, the current study could be replicated for a period longer than 
52 weeks in order to better understand the long term effects of canagliflozin 300 mg. 
Should the results of our proposed study be promising, it would be reasonable to conduct 
a study that further informs a dose-response relationship and help to guide treatment 
protocols. This would be particularly important given our study is testing the effects of 
canagliflozin 300 mg rather than the starting dose of 100 mg. Seeing that those in the 
greater New Haven area are not representative of all those diagnosed with MetS, it would 
also be wise to replicate this study in different populations or across a wider geographic 
area. Regardless of the study outcomes, our proposed trial will provide productive 
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Appendices  
Appendix A: Sample Consent Form 
Created using “Compound Authorization and Consent Template_Biomedical 
Research_1-21-2019”  
 




YALE UNIVERSITY SCHOOL OF MEDICINE, PHYSICIAN ASSOCIATE 
PROGRAM 
YALE-NEW HAVEN HOSPITAL 
 
 
Study Title: Administration of Canagliflozin 300 mg for the Remission of Metabolic 
Syndrome in Nondiabetic Adults  
Principal Investigator (the person who is responsible for this research): Francis P. 
Wilson, MD, MSCE 
Co-Principal Investigator: Corrie Asseo, PA-SII 
24-Hour Phone Number: 203-xxx-xxxx 
 
 
Research Study Summary: 
 
• We are asking you to join a research study. 
• The purpose of this research study is to understand the role of canagliflozin (a 
medication indicated for type 2 diabetes mellitus) for the treatment of metabolic 
syndrome 
• Study procedures will include: 5 in-person visits over a 52-week period. The first visit 
will provide lifestyle modification education and a 90-day supply of either 
canagliflozin or the placebo drug. The first and last visits will include a physical 
examination, blood draws, diet and exercise questionnaires, and a pregnancy test if 
applicable. Each visit in between the first and the last will provide another 90-day 
supply of canagliflozin or the placebo drug and include a physical examination, blood 
draws and a pregnancy test if applicable. Canagliflozin is to be taken one time every 
day for the full 52 weeks.  
• 5 visits of approximately 1 hour each are required. 
• Each visit will take approximately 1 hour total.  
• There are some risks from participating in this study. The most common risks are 
genital mycotic infection, urinary tract infections, and increased urination. Other risks 
include volume depletion, low blood sugar, allergic reaction, kidney injury, and bone 
fracture. Less common risks include acid production. A rare, but serious risk is a 
flesh-eating bacteria infection of the skin between the anus and the genitals. 
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Canagliflozin has a Black Box Warning for lower limb amputations. Other risks can 
be found later in the document.  
• The benefits you may experience include improved health outcomes.  
• There are other choices available to you outside of this research. These choices 
include lifestyle changes, seeking treatment from your physician, partaking in another 
study, or not seeking treatment at all. Alternative treatments that may be provided by 
your physician include an array of drugs to target each of your metabolic 
abnormalities (statins, weight loss drugs, diuretics, etc). Please note that the treatment 
being offered in this study is not currently available as a treatment for metabolic 
syndrome in the United States. 
• Taking part in this study is your choice. You can choose to take part, or you can 
choose not to take part in this study.  You can also change your mind at any time.  
Whatever choice you make, you will not lose access to your medical care or give up 
any legal rights or benefits.  
• If you are interested in learning more about the study, please continue reading, or 
have someone read to you, the rest of this document. Take as much time as you need 
before you make your decision. Ask the study staff questions about anything you do 
not understand. Once you understand the study, we will ask you if you wish to 
participate; if so, you will have to sign this form. 
 
Why is this study being offered to me? 
 
We are asking you to take part in a research study because you meet the criteria for the 
diagnosis of metabolic syndrome and you do not have type 2 diabetes mellitus. We are 
looking for 228 participants to be part of this research study.  
 




What is the study about?  
 
The purpose of this study is to test how well canagliflozin works for the treatment of 
metabolic syndrome. Canagliflozin is not currently approved for the use or treatment of 
metabolic syndrome in the United States.  
 
What are you asking me to do and how long will it take?  
 
If you agree to take part in this study, this is what will happen:  
• This study is expected to take place over 52 weeks (12 months).  
• Women of childbearing age are required to practice an acceptable method of birth 
control: tubal ligation, transdermal patch, intrauterine device/system, oral, 
implantable, or injectable contraceptives, sexual abstinence, double barrier 
method, vasectomy of partner 
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• First, you will meet with one of our study physicians who will conduct an 
interview and physical examination to determine the status of your health and 
your baseline criteria. Women of childbearing age will take a pregnancy test. You 
will also meet with a lab assistant who will draw approximately four tablespoons 
of blood. This process will occur at each in-person visit, which will occur every 3 
months until the end of the 12-month study (a total of 5 visits). At this visit you 
will also complete two questionnaires. One will be regarding your diet over the 
past month, and the other will be regarding your exercise habits over the past 
week. The purpose of these questionnaires is to establish your baseline habits at 
the start of the study.  
• At your first visit, you will receive lifestyle modification education, as well as a 
90-day supply of either our treatment drug (canagliflozin 300 mg) or our placebo 
drug. Canagliflozin is a drug typically prescribed to people with type 2 diabetes 
mellitus. A placebo drug is an inactive drug (without medication) that will appear 
identical to the treatment drug. You will be asked to take this drug once a day 
every day until your next in-person visit where you will receive your next 90-day 
supply.  
• You can expect each in-person visit to take approximately 1 hour: 20 minutes for 
interview, 20 minutes for physical examination, 20 minutes for blood draw.  
• In-person visits will take place at the Church Street Research Unit in New Haven, 
CT 
• You will be asked to speak with a research assistant on the phone once a month 
(in between the in-person visits) to discuss any questions or concerns you may 
have. This could include side effects that you may be experiencing.  
• At your last visit, you will again participate in an interview and physical 
examination conducted by a physician, as well as have your blood drawn by a lab 
assistant. You will also repeat the diet and exercise questionnaires.  
• To ensure the data collection is not influenced by either the research participants 
or the researchers, neither you nor the researchers will know whether you are 
taking canagliflozin or the placebo drug. This method of concealment is called 
“double blinding.” The decision of whether you receive the treatment or the 
placebo will be left to a computer-generated randomization technique. Half of the 
participants will receive the treatment, and half will receive the placebo.  
 
What are the risks and discomforts of participating?  
 
• The most common risks associated with the study drug are genital mycotic 
infection, urinary tract infections, and increased urination. Other risks include 
volume depletion, low blood sugar, allergic reaction, kidney injury and bone 
fracture. Less common risks include acid production. A rare, but serious risk of 
canagliflozin is a flesh-eating bacterial infection of the skin between the anus and 
the genitals.  
• Canagliflozin has a Black Box Warning for lower limb amputations (most often 
of the toe and midfoot). Lower limb amputations are more likely to occur if you 
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have had a prior amputation, or currently have vascular diseases, a lower limb 
infection or ulcer.  
• Please be aware that some of these risks have occurred more often in people with 
multiple diseases or taking other drugs known to have an interaction. These 
people have likely been excluded from this study.  
• Risks to pregnant women are unknown. For this reason, use of birth control in 
women of childbearing age is required for this study.  
• There is a small risk of discomfort, bruising, bleeding, redness, and/or swelling at 
the site of the needle stick during blood draw. Lightheadedness may occur during 
this event. Rarely, infection at the site can occur. 
• There is always a possibility of financial risk if harm or illness occurs. 
Participants or their insurance would be required to pay for treatment. The cost of 
getting to and from in-person visits should be considered.  
 
How will I know about new risks or important information about the study?  
 
We will tell you if we learn any new information that could change your mind about 
taking part in this study.  
 
How can the study possibly benefit me? 
 
You may experience improved health outcomes as a result of this study.  
 
How can the study possibly benefit other people? 
 
The benefits to science and other people may include a better understanding of the use of 
canagliflozin for the treatment of metabolic syndrome. Benefits also include 
advancement in the knowledge of canagliflozin’s side effects on certain populations.  
 
Are there any costs to participation?  
 
If you take part in this study, you will not have to pay for any services, supplies, study 
procedures, or care that are provided for this research only (they are NOT part of your 
routine medical care).  However, there may be additional costs to you.  These can include 
costs of transportation and your time to come to the study visits. You or your health 
insurance must pay for services, supplies, procedures, and care that are part of your 
routine medical care.  You will be responsible for any co-payments required by your 
insurance.   
 
Will I be paid for participation?  
 
You will be paid for taking part in this study. You will be compensated at each in-person 
follow-up visit. At your first 3 follow-up visits, you will receive $100. At your last (fifth) 
visit, you will receive $200. Altogether, you are eligible to receive a total of $500 ($100 
+ $100 + $100 + $200). You are responsible for paying state, federal, or other taxes for 
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the payments you receive for being in this study. Taxes are not withheld from your 
payments. 
 
What are my choices if I decide not to take part in this study? 
 
Instead of participating in this study, you have some other choices.  
You could:  
• Get treatment without being in a study. The treatment being offered in this study 
is not currently approved in the United States, and therefore is not available 
without participating in the study. However, alternative treatments are available. 
These include lifestyle changes, as well as an array of drugs to target each of your 
metabolic abnormalities (statins, weight loss drugs, diuretics, etc).     
• Take part in another study. 
 
How will you keep my data safe and private? 
 
We will keep information we collect about you confidential. We will share it with others 
if you agree to it or when we have to do it because U.S. or State law requires it. For 
example, we will tell somebody if we learn that you are hurting a child or an older 
person. 
 
Your data will be deidentified within 2 weeks of collection of study data and will be kept 
in this form indefinitely. All data will be store on a password-protected computer. Please 
note, after identifiers are removed from the identifiable private information, the 
information could be used for future research studies or distributed to another investigator 
for future research studies without additional informed consent from the subject or the 
legally authorized representative.  
 
When we publish the results of the research or talk about it in conferences, we will not 
use your name. If we want to use your name, we would ask you for your permission.   
 
We will also share information about you with other researchers for future research but 




What Information Will You Collect About Me in this Study? 
 
The information we are asking to use and share is called “Protected Health Information.” 
It is protected by a federal law called the Privacy Rule of the Health Insurance Portability 
and Accountability Act (HIPAA). In general, we cannot use or share your health 
information for research without your permission. If you want, we can give you more 
information about the Privacy Rule. Also, if you have any questions about the Privacy Rule 
and your rights, you can speak to Yale Privacy Officer at 203-432-5919. 
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The specific information about you and your health that we will collect, use, and share 
includes: 
 
• Research study records 
• Medical and laboratory records of only those services provided in connection with 
this Study.   
• The entire research record and any medical records held by YNHH created from: 
[insert start date] to: [insert end date] 
• Records about phone calls made as part of this research 
• Records about your study visits 
• Information obtained during this research regarding 
▪ Hepatitis infection 
▪ Sexually transmitted diseases 
▪ Other reportable infectious diseases 
▪ Physical exams 
▪ Pregnancy status  
▪ Laboratory, x-ray, and other test results 
▪ Diaries and questionnaires 
▪ Use of illegal drugs or the study of illegal behavior 
▪ Records about any study drug you received 
 
How will you use and share my information? 
 
We will use your information to conduct the study described in this consent form.  
We may share your information with: 
• The U.S. Department of Health and Human Services (DHHS) agencies 
• Representatives from Yale University, the Yale Human Research Protection 
Program and the Institutional Review Board (the committee that reviews, approves, 
and monitors research on human participants), who are responsible for ensuring 
research compliance.  These individuals are required to keep all information 
confidential.  
• The U.S. Food and Drug Administration (FDA). This is done so that the FDA can 
review information about canagliflozin involved in this research.  The information 
may also be used to meet the reporting requirements of drug regulatory agencies.   
• The study sponsor or manufacturer of study drug/device 
• Drug regulatory agencies in other countries 
• Governmental agencies to whom certain diseases (reportable diseases) must be 
reported 
• Health care providers who provide services to you in connection with this study. 
• Laboratories and other individuals and organizations that analyze your health 
information in connection with this study, according to the study plan. 
• Co-Investigators and other investigators  
• Study Coordinator and Members of the Research Team  
• Data and Safety Monitoring Boards and others authorized to monitor the conduct of 
the Study  
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We will do our best to make sure your information stays private. But, if we share 
information with people who do not have to follow the Privacy Rule, your information will 
no longer be protected by the Privacy Rule. Let us know if you have questions about this. 
However, to better protect your health information, agreements are in place with these 
individuals and/or companies that require that they keep your information confidential. 
 
Why must I sign this document? 
 
By signing this form, you will allow researchers to use and disclose your information 
described above for this research study. This is to ensure that the information related to this 
research is available to all parties who may need it for research purposes. You always have 
the right to review and copy your health information in your medical record.  
 
However, this is a double blinded treatment study and if you sign this permission form, 
you will not be allowed to look at or copy your study related information until after the 
research is completed 
 
What if I change my mind? 
 
The authorization to use and disclose your health information collected during your 
participation in this study will never expire.  However, you may withdraw or take away 
your permission at any time. You may withdraw your permission by telling the study staff 
or by writing to Francis P. Wilson, MD, MSCE at the Yale University, New Haven, CT 
06520. 
 
If you withdraw your permission, you will not be able to stay in this study but the care you 
get from your doctor outside this study will not change.  No new health information 
identifying you will be gathered after the date you withdraw. Information that has already 
been collected may still be used and given to others until the end of the research study to 
insure the integrity of the study and/or study oversight.   
 
Who will pay for treatment if I am injured or become ill due to participation in the 
study?  
 
If you are injured or become ill during the course of the study, seek treatment and contact 
one of the study physicians as soon as possible.  
 
Yale does not provide any form of compensation for injury or loss of income as a result 
of the study. Should you become ill or injured, treatment will be provided. You or your 
insurance will be expected to cover the cost of this treatment.  
 
What if I want to refuse or end participation before the study is over?  
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Taking part in this study is your choice. You can choose to take part, or you can choose 
not to take part in this study.  You also can change your mind at any time.  Whatever 
choice you make, you will not lose access to your medical care or give up any legal rights 
or benefits.  
 
We would still treat you with standard therapy or, at your request, refer you to a clinic or 
doctor who can offer this treatment. Not participating or withdrawing later will not harm 
your relationship with your own doctors or with this institution.   
 
To withdraw from the study, you can call a member of the research team at any time and 
tell them that you no longer want to take part.   
 
The researchers may withdraw you from participating in the research if necessary. This 
may occur if you begin to experience serious side effects or adverse events as previously 
mentioned.  
 
What will happen with my data if I stop participating? 
 
Because all data will be deidentified once collected, your data will not be able to be 
withdrawn from the study should you stop participating.  
 
Who should I contact if I have questions?  
 
Please feel free to ask about anything you don't understand.  
 
If you have questions later or if you have a research-related problem, you can call the 
Principal Investigator at 201-xxx-xxxx 
 
If you have questions about your rights as a research participant, or you have complaints 
about this research, you call the Yale Institutional Review Boards at (203) 785-4688 or 
email hrpp@yale.edu. 
 
A description of this clinical trial will be available on http://www.ClinicalTrials.gov, as 
required by U.S. Law. This Web site will not include information that can identify you. 
At most, the Web site will include a summary of the results. You can search this Web site 
at any time. 
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Authorization and Permission 
 
Your signature below indicates that you have read this consent document and that you 
agree to be in this study.   
 
We will give you a copy of this form. 
 
 
Participant Printed Name  Participant Signature  Date 
Person Obtaining Consent Printed 
Name 






Complete if the participant is not fluent in English and an interpreter was used to 
obtain consent.  Participants who do not read or understand English must not sign this 
full consent form, but instead sign the short form translated into their native 
language.  This form should be signed by the investigator and interpreter only.  If the 
interpreter is affiliated with the study team, the signature of an impartial witness is also 
required. 
 
Print name of interpreter: ______________________________________ 
 
Signature of interpreter: ___________________________________    Date: 
_________ 
 
An oral translation of this document was administered to the participant in 
_____________ (state language) by an individual proficient in English and 
____________ (state language).  
Print name of impartial witness: __________________________________ 
 
Signature of impartial witness: ________________________________Date: 
_________ 
 
See the attached short form for documentation. 
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Appendix B: Sample Recruitment Flyer  
 
Volunteers Needed for Participation in Research Study 
We are investigating the use of canagliflozin (a type 2 diabetes mellitus medication) for 
the treatment of metabolic syndrome.  
 
Who can participate? 
Adults (18-65 years) with a diagnosis of metabolic syndrome but do not have type 2 
diabetes mellitus.  
 
What will be asked of you? 
You will be asked to take a medication once a day for 52 weeks. Our research team will 
contact you once monthly by telephone to check in. Every 3 months you will be asked to 
come to our office for an in-person follow-up visit and blood will be collected.   
 
How will I be compensated?  
You are eligible to receive up to $500 upon completion of the study. This will be 
distributed in increments throughout the course of the study.  
 
If you are interested in participating or have any 
questions, please do not hesitate to contact us at:  
203-xxx-xxxx or researchteam@yale.edu
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Appendix C: Link to “Past Month with Portion Size” DHQIII  
The link for the “Past Month with Portion Size” DHQIII can be found here: 
https://epi.grants.cancer.gov/dhq3/dhq3-past-month-with-serving-sizes-questionnaire.pdf  
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The protocol for the Stanford 7-Day PAR can be found here: 
https://drjimsallis.org/Documents/Measures_documents/7daypar_protocol.pdf  
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Appendix E: Sample Size Calculation
 
The sample size was calculated* using the following parameters: 
Alpha: 0.5 (two-sided hypothesis) 
Beta: 0.20 
Power of 80% 
Effect size of 15% 
Factoring in a 15% drop out rate, the final sample size is 228 
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